ESH 2014: Prof. Stephan Stilgenbauer Reviews P... - CLL Support

CLL Support

23,086 members39,645 posts

ESH 2014: Prof. Stephan Stilgenbauer Reviews Predictive and Prognostic Markers in CLL

bkoffman profile image
bkoffmanCLL CURE Hero
1 Reply

Friends,

The novel therapies offers the possibility of changing everything, but the reality of the CLL world is slow in catching up. On my blog, bkoffman.blogspot.com , Professor Stilgenbauer reviews how the significance of predictive and prognostic factors may differ in the world of chemo-immunotherapy versus the novel therapies such as ibrutinib or idelalisib.

Please take a moment to check out the post that includes references to some of the original research on prognostic factors.

Happy Hanukkah to my jewish friends.

Brian

bkoffman.blogspot.com

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
AussieNeil profile image
AussieNeilPartnerAdministrator

Thanks Brian; lots of good info there. A rapid unravelling of the mystery of what treatments work best for the different CLL genome variants will be a huge breakthrough for those facing treatment. Your statement

"One possible example seems to be that patients with 17p deletion respond differently when treated upfront with ibrutinib versus when treated after they have relapsed with 17p deletion." is particularly encouraging. How good it will be to have hard evidence on which is the best path - which is presumably treatment prior to relapse. Having effective diagnostic testing can't come fast enough in my opinion.

Neil

Not what you're looking for?

You may also like...

ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL

Friends, I am stuck at the airport on my way to OSU waiting for my delayed flight, so I thought I...

Initiation and Discontinuation of Ibrutinib in Chromic Lymphocytic Leukemia (CLL)

Friends, I found this discussion from OncLive that I just shared on blog:...

BTK Inhibitor Therapy for CLL: An International Perspective - Stephan Stilgenbauer, MD

BTK Inhibitor Therapy for CLL: An International Perspective Stephan Stilgenbauer, MD Expert...

Latest results and musing on my own blood work

Hi friends, I have gotten out of the habit of posting my personal news and musings on my own...

Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients

This breakthrough designation - only for relapsed/refractory 17p deletion patients should mean the...